Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Tyenne
Generic Name
Tocilizumab-aazg
Active Ingredient
TocilizumabCategory
Interleukin-6 Receptor Antagonist [EPC]
Variants
7
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Tyenne, you must consult a qualified healthcare professional.
| 65219-594 |
| 162 mg/.9mL | INJECTION, SOLUTION | SUBCUTANEOUS | 65219-586 |
| 162 mg/.9mL | INJECTION, SOLUTION | SUBCUTANEOUS | 65219-584 |
| 162 mg/.9mL | INJECTION, SOLUTION | SUBCUTANEOUS | 65219-598 |
| 200 mg/10mL | INJECTION, SOLUTION, CONCENTRATE | INTRAVENOUS | 65219-592 |
Detailed information about Tyenne
Tocilizumab is a recombinant humanized monoclonal antibody that acts as an Interleukin-6 (IL-6) receptor antagonist, used to treat various inflammatory conditions including rheumatoid arthritis and cytokine release syndrome.
Dosage for Tocilizumab is highly individualized and often depends on the patient's total body weight and the specific condition being treated. For Rheumatoid Arthritis (RA), the typical intravenous starting dose is 4 mg/kg administered every 4 weeks, which may be increased to 8 mg/kg every 4 weeks based on clinical response, not to exceed 800 mg per infusion. For subcutaneous administration in RA, patients weighing less than 100 kg (220 lbs) usually start with 162 mg every other week, increasing to every week based on response. Those over 100 kg typically start with 162 mg every week. For Giant Cell Arteritis (GCA), the standard dose is 162 mg given once weekly via subcutaneous injection in combination with a tapering course of glucocorticoids (steroids). In cases of Cytokine Release Syndrome (CRS), the dose is typically 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients <30 kg) administered intravenously, with the potential for repeat doses if symptoms do not improve.
Tocilizumab is approved for specific pediatric conditions in children aged 2 years and older. For Systemic Juvenile Idiopathic Arthritis (SJIA), the intravenous dose for children weighing less than 30 kg is 12 mg/kg every 2 weeks; for those 30 kg or greater, the dose is 8 mg/kg every 2 weeks. For Polyarticular Juvenile Idiopathic Arthritis (PJIA), the intravenous dose is 10 mg/kg (for <30 kg) or 8 mg/kg (for ≥30 kg) every 4 weeks. Subcutaneous dosing schedules also exist for these pediatric populations and are strictly weight-based. Healthcare providers must carefully calculate these doses to ensure safety and efficacy in growing children. Use in children under 2 years of age has not been established for these conditions.
No formal studies have been conducted in patients with severe renal (kidney) impairment. However, because Tocilizumab is not cleared by the kidneys, dose adjustments are generally not required for patients with mild to moderate renal impairment. Your doctor will monitor your kidney function (creatinine levels) regularly.
The safety and efficacy of Tocilizumab have not been studied in patients with hepatic (liver) impairment. Because Tocilizumab can cause elevations in liver enzymes, it is not recommended for patients with active liver disease or significant hepatic impairment. Healthcare providers will typically delay or stop treatment if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceed 3 to 5 times the upper limit of normal.
In clinical trials, no overall differences in safety or effectiveness were observed between patients over 65 and younger patients. However, because the risk of infection is generally higher in the elderly population, healthcare providers use caution when prescribing Tocilizumab to this demographic.
If you are receiving the Intravenous Infusion, you will visit a clinic or infusion center. The procedure takes about one hour. If you are using the Subcutaneous Injection at home:
If you miss a dose of the subcutaneous injection, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not 'double up' on doses. If you miss an infusion appointment, contact your healthcare provider immediately to reschedule.
There is limited data regarding Tocilizumab overdose. Because it is an injectable biologic, accidental massive overdose is rare. Symptoms of an overdose would likely involve an exaggerated immune suppression, increasing the risk of severe infection. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without direct medical guidance.
Side effects are a common occurrence with biological therapies as the body adjusts to the modulation of the immune system. According to clinical trial data, the most frequently reported side effects include:
Tocilizumab is a potent immunomodulator that requires careful medical oversight. The most critical safety consideration is the drug's effect on the body's ability to fight infection. Because Tocilizumab blocks Interleukin-6, it can mask the typical signs of infection. For example, IL-6 is necessary for the development of a fever; therefore, a patient on Tocilizumab might have a serious infection without running a high temperature. Patients and caregivers must be educated to look for more subtle signs of illness, such as malaise, localized pain, or a general feeling of being unwell.
SERIOUS INFECTIONS: Patients treated with Tocilizumab are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
There are no absolute drug-drug contraindications listed by the FDA that require complete avoidance; however, the use of Live Vaccines is strictly contraindicated during treatment. Because Tocilizumab suppresses the immune response, a live vaccine could potentially cause the disease it is intended to prevent or lead to a severe systemic infection. Examples include the intranasal flu vaccine, the MMR vaccine, and the shingles (Zostavax) vaccine (note: Shingrix is not a live vaccine and is generally considered safe).
There are specific clinical scenarios where Tocilizumab must NEVER be used:
These conditions require a careful 'risk-benefit' analysis by a specialist:
Tocilizumab is classified under a cautious approach regarding pregnancy. Data from the 'Antirheumatic Therapies in Pregnancy and Breastfeeding' guidelines suggest that while monoclonal antibodies (IgG) do cross the placenta, this primarily occurs during the second and third trimesters. There is limited data on whether Tocilizumab causes birth defects or miscarriage in humans. Animal studies using monkeys showed an increased risk of embryo-fetal death at high doses. Healthcare providers typically recommend using Tocilizumab during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are planning a pregnancy, discuss a 'washout' period or alternative therapies with your rheumatologist.
It is not known if Tocilizumab is excreted in human milk in significant amounts. However, because it is a large protein molecule, any amount swallowed by the infant would likely be degraded in the infant's digestive tract before being absorbed. Current clinical consensus suggests that breastfeeding while taking Tocilizumab is likely low risk, but a shared decision-making process between the mother and the healthcare provider is essential. The infant should be monitored for signs of infection or diarrhea.
Tocilizumab is a recombinant humanized IgG1κ monoclonal antibody. Its primary molecular target is the Interleukin-6 receptor (IL-6R). IL-6 is a pleiotropic (multi-functional) cytokine that mediates various physiological processes, including the 'acute phase response,' T-cell activation, and osteoclast (bone-dissolving cell) differentiation. Tocilizumab binds specifically to both soluble IL-6 receptors (sIL-6R) and membrane-bound IL-6 receptors (mIL-6R). By doing so, it competitively inhibits IL-6 from binding to its receptor complex. This prevents the association of the receptor with the signal-transducing protein gp130, thereby blocking the entire JAK-STAT signaling pathway. This inhibition leads to a reduction in the production of other pro-inflammatory cytokines and a decrease in the systemic inflammatory state.
The most notable pharmacodynamic effect of Tocilizumab is the rapid suppression of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum amyloid A. It also leads to an increase in hemoglobin levels by reducing IL-6-induced production of hepcidin (a hormone that blocks iron absorption). Following a single intravenous dose, IL-6 levels in the blood actually increase because the drug blocks the receptors that would normally clear the IL-6 from circulation; however, this IL-6 is 'neutralized' because it cannot bind to its blocked receptors.
Common questions about Tyenne
Tocilizumab is primarily used to treat several serious inflammatory and autoimmune conditions. Its most common application is for adults with moderately to severely active rheumatoid arthritis who haven't responded well to other treatments. It is also the first biologic drug approved to treat giant cell arteritis, a condition involving inflamed blood vessels. Additionally, it is used in children for juvenile idiopathic arthritis and in hospital settings for cytokine release syndrome caused by cancer therapies. Most recently, it has been utilized for certain hospitalized patients with severe COVID-19 to reduce systemic inflammation.
The most frequently reported side effects of Tocilizumab include upper respiratory tract infections, such as the common cold and sinus infections. Many patients also experience headaches, increased blood pressure, and nasopharyngitis (inflammation of the nose and throat). For those using the subcutaneous injection form, redness or itching at the injection site is very common. Laboratory changes, such as increased cholesterol levels and mild elevations in liver enzymes, are also frequently seen during routine blood monitoring. Most of these common side effects are manageable, but they should always be discussed with your healthcare provider.
There is no known direct chemical interaction between Tocilizumab and alcohol; however, caution is strongly advised. Tocilizumab is known to cause elevations in liver enzymes and, in rare cases, serious liver injury. Because alcohol also puts stress on the liver, consuming it while on this medication may increase your risk of hepatotoxicity. Most healthcare providers recommend limiting alcohol intake or avoiding it entirely if your liver enzyme tests are already elevated. Always consult your doctor about what level of alcohol consumption is safe for your specific health profile.
The safety of Tocilizumab during pregnancy is not fully established, and it is generally used only if the benefits outweigh the potential risks. Animal studies have shown that high doses may be linked to an increased risk of pregnancy loss. While there is no definitive evidence of birth defects in humans, the drug is known to cross the placenta in the later stages of pregnancy. Women of childbearing age are often advised to use effective contraception during treatment and for several months after the last dose. If you become pregnant while taking Tocilizumab, you should notify your rheumatologist immediately.
The onset of action for Tocilizumab can vary depending on the condition being treated and the individual patient. Many patients with rheumatoid arthritis begin to feel an improvement in joint pain and swelling within 2 to 4 weeks of starting therapy. However, the full clinical benefits of the medication often take 3 to 6 months to be realized. Laboratory markers of inflammation, such as C-reactive protein (CRP), typically drop very quickly, often within days of the first dose. It is important to continue the medication as prescribed, even if you do not feel immediate relief.
You should never stop taking Tocilizumab suddenly without first consulting your healthcare provider. While Tocilizumab does not cause a physical withdrawal like some other medications, stopping it can cause a significant 'flare' of your underlying disease. This means your joint pain, stiffness, or vascular inflammation could return rapidly and potentially more severely than before. If you need to stop the medication due to a scheduled surgery or a serious infection, your doctor will provide a specific plan. Always discuss your concerns about the medication with your medical team before making any changes.
If you miss a scheduled subcutaneous injection of Tocilizumab, you should take it as soon as you remember, provided your next dose isn't due very soon. If it is almost time for your next dose, simply skip the missed one and return to your regular schedule. Do not take two doses at once to make up for a missed one. If you miss an appointment for an intravenous infusion, call your doctor or infusion center immediately to reschedule. Keeping a consistent level of the drug in your system is vital for controlling chronic inflammation.
Weight gain is not a commonly reported side effect of Tocilizumab in clinical trials. However, some patients may experience weight changes indirectly. For example, as the drug successfully reduces inflammation and joint pain, a patient's mobility and appetite may improve, leading to some weight gain. Additionally, Tocilizumab is often taken in combination with corticosteroids (like prednisone), which are well-known to cause significant weight gain and fluid retention. If you notice rapid or unusual weight gain, you should discuss it with your doctor to determine the underlying cause.
Tocilizumab can be taken with many other medications, but it has several important interactions. It is frequently prescribed alongside methotrexate or other non-biologic DMARDs. However, it should never be combined with other 'biologic' drugs or JAK inhibitors due to the extreme risk of infection. A unique interaction exists with drugs like warfarin and statins; because Tocilizumab changes how your liver processes these drugs, their doses may need to be adjusted. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are using.
As of 2024, there are no 'generic' versions of Tocilizumab in the traditional sense because it is a complex biological drug. Instead, versions made by other companies are called 'biosimilars.' Several biosimilars for Tocilizumab (such as Tofidence and Tyenne) have received FDA approval. These biosimilars are highly similar to the original Actemra in terms of safety, purity, and potency. Depending on your insurance coverage and local availability, your healthcare provider may prescribe either the original brand or one of these approved biosimilars.
Other drugs with the same active ingredient (Tocilizumab)
These side effects occur in a smaller percentage of the population but still require clinical awareness:
Rare but clinically significant events include:
> Warning: Stop taking Tocilizumab and call your doctor immediately if you experience any of these symptoms.
Prolonged use of Tocilizumab requires ongoing vigilance. Long-term risks include an increased susceptibility to opportunistic infections (infections that occur more frequently in people with weakened immune systems). There is also a theoretical risk of malignancies (cancers), as the immune system plays a role in surveillance against tumor cells, though current data has not shown a definitive increase in cancer rates compared to other biologics. Chronic elevation of lipid levels (cholesterol) may also increase cardiovascular risk if not managed with diet or medication.
Tocilizumab carries an FDA Black Box Warning regarding the risk of serious infections. Patients treated with Tocilizumab are at increased risk for developing serious infections that may lead to hospitalization or death. These include active tuberculosis, which may present with a cough that won't go away; invasive fungal infections, such as candidiasis or aspergillosis; and other bacterial or viral infections. Patients should be tested for latent tuberculosis before starting Tocilizumab and monitored for signs of active TB during treatment. If a serious infection develops, Tocilizumab should be discontinued until the infection is controlled.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately to ensure safe continuation of therapy.
To ensure safety, healthcare providers will require regular blood tests. The standard monitoring schedule typically includes:
Tocilizumab generally does not affect the ability to drive or operate machinery. However, if you experience dizziness or fatigue as a side effect, you should avoid these activities until you know how the medication affects you.
While there is no direct contraindication between Tocilizumab and alcohol, both substances can stress the liver. Since Tocilizumab is known to cause liver enzyme elevations, excessive alcohol consumption may increase the risk of hepatotoxicity. Discuss your alcohol intake with your doctor.
Do not stop taking Tocilizumab without consulting your doctor. While there is no 'withdrawal syndrome' like that seen with opioids or steroids, stopping the drug can lead to a rapid 'flare' or worsening of your underlying inflammatory condition. If treatment must be stopped due to a serious infection, your doctor will provide a plan for when it is safe to restart.
> Important: Discuss all your medical conditions, especially a history of infections or liver disease, with your healthcare provider before starting Tocilizumab.
There are no known significant interactions between Tocilizumab and specific foods. Unlike some medications, Tocilizumab is not affected by grapefruit juice or dairy products. However, maintaining a heart-healthy diet is recommended because Tocilizumab can increase cholesterol levels.
For each major interaction, the management strategy usually involves more frequent monitoring of the co-administered drug's levels or clinical effects (e.g., checking blood pressure more often or performing more frequent blood clotting tests).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
While Tocilizumab is a humanized antibody, patients who have had reactions to other monoclonal antibodies (like Rituximab or Infliximab) may be at a slightly higher risk for hypersensitivity, though there is no direct cross-reactivity between these different protein structures. Patients with a known allergy to rubber or latex should be aware that the needle caps on the pre-filled syringes may contain dry natural rubber.
> Important: Your healthcare provider will evaluate your complete medical history, including past infections and surgical history, before prescribing Tocilizumab.
Patients over the age of 65 are at a naturally higher risk for infections and malignancies. In clinical trials, while the efficacy of Tocilizumab was similar to younger adults, the frequency of serious infections was higher. Furthermore, elderly patients are more likely to have decreased renal or hepatic reserve and are often on multiple other medications (polypharmacy), increasing the risk of drug interactions. Close monitoring of blood pressure and infection signs is paramount in this age group.
For patients with mild to moderate renal impairment, no dose adjustment is necessary. Tocilizumab is a large protein and is not cleared by the kidneys via glomerular filtration. There is no data for patients with end-stage renal disease (ESRD) or those on dialysis. Clearance in these patients is likely handled by the reticuloendothelial system, but clinical caution is advised.
Tocilizumab is not recommended for patients with significant hepatic impairment. The drug's potential to cause liver enzyme elevations can exacerbate pre-existing liver damage. In patients who develop elevated enzymes during treatment, the dose is often reduced from 8 mg/kg to 4 mg/kg or interrupted entirely until levels normalize.
> Important: Special populations require individualized medical assessment and more frequent clinical monitoring.
| Parameter | Value |
|---|---|
| Bioavailability | 80% (Subcutaneous) |
| Protein Binding | Negligible (it is a protein itself) |
| Half-life | 11-13 days (IV), 18 days (SC) |
| Tmax | 2 to 4 days (Subcutaneous) |
| Metabolism | Proteolysis (Reticuloendothelial system) |
| Excretion | Non-linear (receptor-mediated) and Linear |
Tocilizumab has a molecular weight of approximately 148,000 Daltons. It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The structure consists of two heavy chains and two light chains linked by disulfide bonds. It is highly soluble in aqueous buffers and is formulated at a pH of approximately 6.0 to ensure stability and minimize aggregation.
Tocilizumab is the flagship member of the Interleukin-6 Receptor Antagonist class. Related medications that target the IL-6 pathway include Sarilumab (Kevzara), which also targets the receptor, and Siltuximab (Sylvant), which binds directly to the IL-6 cytokine itself rather than the receptor.